On August 19, St. Jude Medical, Inc. announced the acquisition of Endosense SA. The press release notes that St. Jude Medical has made an initial payment of approximately $170 million with additional cash payments of up to $161 million contingent on achievement and timing of regulatory milestones.
According to the press release, Endosense SA, a Switzerland-based company, “has pioneered contact-force measurement in catheter ablation.” The press release notes that Endosense’s TactiCath irrigated ablation catheter provides physicians a real-time, objective measure of the force applied to the heart wall during a catheter ablation procedure.
Frank J. Callaghan, president of the Cardiovascular and Ablation Technologies Division of St. Jude Medical stated:
This transaction significantly accelerates our timeline to providing an irrigated ablation catheter that incorporates force sensing in both international and U.S. markets, and has potential future applications across other St. Jude Medical technology platforms as well.
The press release states that St. Jude Medical can incorporate the force sensing technology for use with their technologies including offering a “MediGuide-enabled force-sensing ablation catheter and to incorporate force sensing data into the company’s EnSite Velocity™ Mapping System.”